Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1812 in mild to moderate Alzheimer's disease
NL-OMON53705Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zervimesine in Alzheimer's disease (AD) (3 arms), sponsored by Cognition Therapeutics, Inc. Primary endpoints: Incidence and severity of adverse events, Vital signs and 22 more. Started Nov 2022; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON53705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53705.